Significance of haemostatic markers in ovarian carcinoma

Abstract

Background: Most cancer patients with metastatic disease have abnormal coagulation parameters. Although many abnormal blood coagulation tests have been reported in malignancies, there is little agreement regarding which tests are most useful to predict disease progression and hence this study was undertaken. Methods: In this prospective study, baseline and special coagulation tests were performed on 23 patients with ovarian adenocarcinoma. The baseline tests were PT, APTT, TT and platelet count. The special tests included factor VIII, factor IX and fibrinogen assay and semiquantitative measurement of D-dimer and FDP levels The cases were grouped into early and advanced disease groups. The results of the coagulation tests were analysed using suitable statistical methods. The results were compared between limited and advanced disease by chi square and Mann Whitney U test Results: The percentage of cases with increased D-dimer and fibrin degradation products (FDP) values were higher in the advanced disease compared to early disease. Two cases in stage IV had DIC. The PT, APTT, TT and platelet count did not show any statistically significant differences between the early and advanced disease groups. Factor VIII, factor IX and fibrinogen levels were not significantly different between two groups. Conclusion: Elevated D dimer& FDP are associated with advanced stage ovarian adenocarcinoma.

D-Dimer Levels In Breast Carcinoma: A Clinico-Pathologic Study

“…However, studies done by Dirix et al [9] and Blackwell et al [4] found no significant association between the two. (Table 4) Various studies have shown that D-dimer levels are increased in cancer patients as compared to the control population [1,5,7] which was comparable to our findings of higher D-dimer levels in cases as opposed to controls. Higher levels of D-dimer have also been observed in patients with regional and distant metastatic disease, shortened survival time and higher stage.…”

“…[10] Some of the studies done on carcinoma breast that have tested for the correlation between D-dimer levels and various histopathological prognostic factors have documented varied results. [1,4,7] In our study, we found a strong correlation between D-dimer levels and lymph node involvement as well as tumour grade. Being a non-invasive and inexpensive test, D-dimer levels can be estimated with ease and is potentially a good prognostic test to be used in routine clinical practice in conjunction with other prognostic markers.…”

“…5, Issue 3, March, 2018 major challenge to the clinician which may be in the form of thrombosis or excessive bleeding. [1,7,8] …”

Efficacy and safety of antifibrinolytics in oncological surgery: a systematic review and meta-analysis

“…It is essential to document the safety of the antifibrinolytic agent because it blocks the breakage of fibrin by preventing the binding of the plasminogen-plasmin tissue activator complex, thus facilitating the formation of the clot. 29 This mechanism raised concerns about the potential to increase thromboembolic events in a population that has procoagulant factors.…”

D-Dimer and Fibrinogen in Patients Underwent Surgery in Malignant and Benign Ovarian Tumor

“…Abnormalities in blood coagulation have been found in 92% of cancer patients. The most frequent abnormality is an increase in the value of clotting factors, such as fibrinogen as well as factors V, VII, IX and X, and also an increase in fibrinogen/fibrin degradation 3 products, D-dimer, and thrombocytosis. D-dimer is the final product and a specific f i b r i n o l y s i s m a r k e r w i d e l y e v a l u a t e d i n thromboembolism studies but still investigated in studies of progressive systemic inflammatory responses and multi-organ dysfunction in critical illness and assessment of carcinoma progression.…”